New Drug Candidates for Treatment of Atypical Meningiomas: an Integrated Approach Using Gene Expression Signatures for Drug Repurposing

Zsolt Zador, Andrew King, Nophar Geifman

Research output: Contribution to journalArticlepeer-review

Abstract

Background
Atypical meningiomas are common central nervous system neoplasms with high recurrence rate and poorer prognosis compared to their grade I counterparts. Surgical excision and radiotherapy remains the mainstay therapy but medical treatments are limited. We explore new drug candidates using computational drug repurposing based on the gene expression signature of atypical meningioma tissue with subsequent analysis of drug-generated expression profiles. We further explore possible mechanisms of action for the identified drug candidates using ingenuity pathway analysis (IPA).

Methods
We extracted gene expression profiles for atypical meningiomas (12 samples) and normal meningeal tissue (4 samples) from the Gene Expression Omnibus, which were then used to generate a gene signature comprising of 281 differentially expressed genes. Drug candidates were explored using both the Board Institute Connectivity Map (cmap) and Library of Integrated Network-Based Cellular Signatures (LINCS). Functional analysis of significant differential gene expression for drug candidates was performed with IPA.

Results
Using our integrated approach, we identified multiple, already licensed, drug candidates such as emetine, verteporfin, phenoxybenzamine and trazodone. Analysis with IPA revealed that these drugs target signal cascades potentially relevant in pathogenesis of meningiomas, particular examples are the effect on ERK by trazodone, MAP kinases by emetine, and YAP-1 protein by verteporfin.

Conclusion
Gene expression profiling and use of drug expression profiles have yielded several plausible drug candidates for treating atypical meningioma, some of which have already been suggested by preceding studies. Although our analyses suggested multiple anti-tumour mechanisms for these drugs, further in vivo studies are required for validation.
Original languageEnglish
JournalPLoS ONE
Early online date20 Mar 2018
DOIs
Publication statusPublished - 2018

Keywords

  • Atypical meningioma
  • drug repurposing
  • ingenuity pathway analysis
  • Gene expression profiling
  • drug expression profile

Fingerprint

Dive into the research topics of 'New Drug Candidates for Treatment of Atypical Meningiomas: an Integrated Approach Using Gene Expression Signatures for Drug Repurposing'. Together they form a unique fingerprint.

Cite this